Calliditas Financial Statements From 2010 to 2025
| CLTEF Stock | USD 0.70 0.15 27.27% |
Check Calliditas Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calliditas Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Calliditas financial statements analysis is a perfect complement when working with Calliditas Therapeutics Valuation or Volatility modules.
Calliditas |
Calliditas Therapeutics AB Company Current Valuation Analysis
Calliditas Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Calliditas Therapeutics Current Valuation | 496.05 M |
Most of Calliditas Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calliditas Therapeutics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Calliditas Therapeutics AB has a Current Valuation of 496.05 M. This is 96.55% lower than that of the Healthcare sector and 89.32% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 97.02% higher than that of the company.
Calliditas Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Calliditas Therapeutics's current stock value. Our valuation model uses many indicators to compare Calliditas Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Calliditas Therapeutics competition to find correlations between indicators driving Calliditas Therapeutics's intrinsic value. More Info.Calliditas Therapeutics AB is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Calliditas Therapeutics' earnings, one of the primary drivers of an investment's value.About Calliditas Therapeutics Financial Statements
Calliditas Therapeutics stakeholders use historical fundamental indicators, such as Calliditas Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Calliditas Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Calliditas Therapeutics' assets and liabilities are reflected in the revenues and expenses on Calliditas Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Calliditas Therapeutics AB. Please read more on our technical analysis and fundamental analysis pages.
Calliditas Therapeutics AB , a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. Calliditas Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Calliditas Pink Sheet
Calliditas Therapeutics financial ratios help investors to determine whether Calliditas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Calliditas with respect to the benefits of owning Calliditas Therapeutics security.